Mindwalk $HYFT Q4 어닝콜을 주목해야 하는 이유. ReefIQ 보도자료를 살펴보다 눈에 띄는 구절을 발견했다. LensAI is already in contracted, recurring arrangements with life-sciences "customers" today. 계약 고객의 수가 한군데 이상이라는 소리다. 잠시 Q3 어닝콜로 돌아가보자 Recently, our largest enterprise AI client signed a one-year LensAI platform contract, the "first" of its kind for us. 분명 Q3 어닝콜에서는 "첫 고객"이 계약을 체결했다고 했는데, 약 3달 사이에 고객을 지칭하는 말이 복수로 바뀌었다. 회사에서 별도로 적극적인 어필을 하진 않았으나, Q4 어닝콜에서 LensAI 구독 고객의 수와 SaaS 매출이 상승했음을 언급하는지 잘 지켜볼 필요가 있어보인다.

$HYFT $HYFT MindWalk has been busy as hell lately. BioMind. ReefIQ. LensAI. New lab hires. Now a new business development hire. Conference appearances. At some point you start asking yourself… Are they building all this because they’re expecting more opportunities ahead? I don’t know. But companies usually don’t add people to find business if they don’t think there’s business to find.

$HYFT Jennifer Pchelinski는 사업개발 이사로 새롭게 MindWalk에 합류했습니다. 그녀는 직전에 $DHR 산하 Cytiva에서 근무하며 AAV 안정 세포주 서비스의 사업개발을 담당했습니다. AAV는 유전자치료제에서 치료 유전자를 세포 안으로 전달하는 데 쓰이는 바이러스 벡터이고, 안정 세포주는 이를 반복적이고 일관되게 생산하기 위해 필요한 기반입니다. 그녀는 고도의 바이오 생산/연구 서비스를 제약사와 바이오텍 고객에게 소개하고, 미국 주요 지역과 캐나다, APAC 고객을 대상으로 사업 기회를 발굴해온 경험을 보유하고 있습니다. 또한 MTA와 MSA를 다룬 경험도 갖고 있습니다. MTA는 세포주, 항체, 바이러스 벡터, 샘플 같은 생물학적 물질을 한 회사에서 다른 회사로 넘길 때 필요한 물질이전계약입니다. 이 물질을 어떤 목적으로 사용할 수 있는지, 실험 후 폐기해야 하는지, 여기서 나온 데이터와 결과물의 권리는 누구에게 있는지를 정하는 계약입니다. MSA는 연구 서비스나 플랫폼 서비스를 제공할 때 적용되는 기본 서비스 계약입니다. 비용, 일정, 비밀유지, 데이터 소유권, IP 권리, 책임 범위 같은 큰 틀을 먼저 정해두고, 이후 개별 프로젝트는 별도의 작업 범위로 붙이는 구조입니다. 이런 경력은 MindWalk의 상업화 전략과 직접 맞닿아 있습니다. HYFT, LENSai, ReefIQ는 외부 제약사나 바이오텍이 보유한 데이터, 샘플, 연구 과제와 연결될수록 활용 가치가 커지는 플랫폼입니다. 고객을 발굴하고, 기술을 설명하고, 물질/데이터/IP 권리를 정리한 뒤, 실제 서비스 계약이나 공동연구 구조로 전환해본 인력은 MindWalk가 플랫폼을 파트너십과 매출로 연결하는 과정에서 실무적인 이점을 제공합니다.

왜 중요한가? ■처음부터 재사용 가능한 신약 발굴 맥락을 구축한다 팀이 새로운 지식 기반을 구축하든, 수년간 축적된 기존 작업을 보존하든, 신약 발굴은 과학적 맥락을 서로 연결할 수 있는 능력에 달려 있습니다. ReefIQ는 그 맥락을 관리 가능하고 질의 가능한 지식으로 보존하는 데 도움을 줍니다. 새로운 인사이트가 추가될수록, 과거 데이터는 향후 프로그램 전반에서 더 쉽게 재사용/비교/해석될 수 있습니다. ■생물학 전반에서 맥락과 증거를 연결한다 고객 데이터를 서열, 구조, 기능, 메커니즘, 경로, 문헌 맥락과 연결합니다. ■프로그램 기억을 보존한다 폐기되었거나 결론이 나지 않은 작업까지 포함해, 각 프로그램이 학습한 내용을 유지합니다. ■모델이 바로 활용할 수 있는 워크플로우를 지원한다 LensAI 또는 고객이 선택한 AI 워크플로우가 검색, 분석, 가설 생성을 수행할 수 있도록 맥락을 제공합니다.

ReefIQ가 위치하는 곳 ReefIQ는 LensAI와 고객이 선택한 AI 모델 아래에 놓이는 생물학적 컨텍스트 레이어입니다. ReefIQ는 고객의 신약 발굴 데이터와 AI 추론 워크플로우 사이의 가교 역할을 합니다. 데이터를 정합화하고, 이를 HYFT의 생물학적 표현 체계와 연결하며, LensAI 또는 고객이 선택한 AI 모델이 검색하고, 추론하고, 기반으로 삼을 수 있는 구조화되고 추적 가능한 맥락으로 전환합니다. LensAI™는 ReefIQ를 활용해 신약 발굴, 표적 발굴, 설계 및 엔지니어링 워크플로우, 가설 생성, 포트폴리오 의사결정을 지원합니다.

$HYFT Maybe I’m way off here, but it feels like MindWalk keeps taking pieces of the same technology and turning them into separate products. At first it felt like: HYFT. LensAI. That’s it. Now we’ve got BioMind. Now we’ve got ReefIQ. The way I’m reading it, not every customer wants the whole kitchen sink. Some may want the AI. Some may want the biological knowledge network. Some may want the data layer. Some may want everything. Instead of one giant product, it feels like they’re creating multiple ways for customers to get in the door. One technology. Multiple products. Multiple shots at revenue. Just connecting dots.

$HYFT I think today’s ReefIQ announcement went over a lot of people’s heads. The way I understand it, MindWalk isn’t just trying to build another AI model. They’re trying to build a system that remembers everything. Every success. Every failure. Every experiment. Every research paper. Every biological connection. Most research gets buried in folders, databases, and old reports. ReefIQ is designed to connect all of that information together so future discoveries can learn from past discoveries. The simple way I look at it: HYFT finds biological patterns. ReefIQ organizes and connects the knowledge. LensAI uses that knowledge to search for answers. The more information that gets added, the more valuable the system becomes. To me, this sounds less like a single drug company and more like a company trying to build a biological operating system for drug discovery. Now the science has to back it up. That’s why I continue to view dengue neutralization as such an important milestone. The technology story is getting stronger. The biology now has an opportunity to prove it.

$HYFT — ReefIQ™ just dropped, directly targeting the biggest bottleneck in AI drug discovery: fragmented data. This isn't just a new feature; it's a critical strategic enhancement for MindWalk, solidifying their BioIntelligence infrastructure by providing structured, queryable biological context. It significantly strengthens their core HYFT® and LensAI™ platforms, improving their competitive edge in a fast-moving sector. We peeled this 6-K, filed at $1.80, recognizing it as a direct move to accelerate drug development for their partners. Faster, more efficient discovery cycles translate directly into increased platform adoption and potential revenue growth for HYFT. This launch follows a consistent pattern of MindWalk's strategic 6-K filings, indicating active, ongoing expansion of their AI capabilities, such as the recent preclinical data validating their dengue target prediction. This isn't academic tech news; it's a strategic product expansion designed to convert their AI strength into tangible financial upside. Watch for accelerating partnerships and adoption rates. Peeled it before the move. Source & full breakdown: Wiseek (link in bio)

$HYFT ReefIQ turns fragmented biological data into governed, queryable context for AI-enabled drug discovery and biologics development. VICTORIA, British Columbia--(BUSINESS WIRE)-- MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today launched ReefIQ™, a HYFT-powered biological context layer for AI drug discovery and biologics development, that sits between client discovery data and AI reasoning workflows. Biology is connected, but drug-discovery data is often fragmented across files, formats, systems, teams, and workflows. ReefIQ reconnects those representations before AI workflows act on them, linking fragmented data into MindWalk's biological representation foundation. Sequences, structures, assay outputs, omics, literature, evidence, provenance, and program history are transformed into a governed, queryable connected biological context for AI-enabled discovery. "In life-sciences AI, the durable advantage is not the model a team licenses but the biological context it can reason over. Biology is connected by evolutionary constraint; discovery data arrives fragmented across files and systems, and that gap is where insight is lost. ReefIQ is designed to close it, preserving what every program learns, including the programs that fail, as governed context rather than isolated files. In a regulated setting, that is what makes reasoning trustworthy, and trustworthy is what compounds into the clinic," said Dr. Jennifer Bath, PhD, CEO and President of MindWalk Holdings Corp. LensAI and customer-selected agent models can then retrieve, analyze, and generate hypotheses from connected biological context rather than isolated files. HYFT® is MindWalk’s core biological pattern technology. It provides the underlying biological representation foundation with explicit relationships across sequence, structure, function, mechanism, pathway, evidence, and literature. ReefIQ™ is the client biological context layer built on HYFT. It harmonizes client discovery data, links it to MindWalk’s biological representation foundation, preserves provenance and program history, and exposes governed, queryable context to LensAI and customer-selected agent models. LensAI™ is the reasoning and application layer. It uses ReefIQ’s connected biological context to support retrieval, analysis, target discovery, candidate diligence, hypothesis generation, and portfolio decision support. HYFT powers the biological representation. ReefIQ organizes and governs the context. LensAI applies reasoning workflows. Why this layer matters Drug-discovery organizations generate valuable context in every program: positive results, negative results, assay conditions, design decisions, mechanism hypotheses, literature links, and reasons candidates did not advance. ReefIQ preserves that context as governed, queryable knowledge. As data are added, the network is enriched and its relationships and annotations are refined. Future programs benefit from the ever-compounding evidence and insights. Inspired by cumulative biological systems A reef grows by connecting what came before into a living structure. ReefIQ uses that metaphor for scientific knowledge: each dataset, result, program, and piece of evidence can become part of a governed context layer for future discovery. “ReefIQ operationalizes the HYFT information network for drug discovery,” said Dirk Van Hyfte, MD, PhD, Chief Technology Officer of MindWalk. “HYFT provides the biological representation foundation, representing the complex relationships in biology; ReefIQ links customer data to that foundation and exposes governed context to LensAI and customer-selected agent models operating within agreed governance. The goal is to support retrieval, analysis, and hypothesis generation over connected biological context while preserving provenance, deployment flexibility, and customer-defined controls.” What comes next ReefIQ™ is designed to become the foundation for MindWalk's future life-sciences engagements: a HYFT-powered biological context layer beneath LensAI™ and client-selected model or agent workflows. The architecture supports flexible integration across data governance, model access, and compute deployment. LensAI is already in contracted, recurring arrangements with life-sciences customers today. Interested parties may request a private briefing through Investor Relations. For more information about the technology, please visit: mindwalkai.com/reefiq

$HYFT MindWalk Holdings launched ReefIQ — a biological context layer for AI drug discovery. Drug discovery data is fragmented across files, teams, and failed programs. ReefIQ connects it into a governed, queryable knowledge graph before AI reasoning workflows act on it. Every program — including failures — compounds into future discovery. Stack: HYFT (660M biological patterns, 25B relationships) → ReefIQ (governs client data) → LensAI (reasoning and hypothesis generation). LensAI already has contracted, recurring revenue with pharma customers. Not financial advice.

$HYFT One thing I keep thinking about is the difference management can make. Before Moderna had an approved product, Stéphane Bancel convinced investors, institutions, and pharmaceutical companies that the platform was worth billions of dollars. By the time COVID arrived, Moderna was already valued at roughly $7 billion. Investors weren't buying revenue. They were buying a vision, a platform, and confidence in management's ability to execute. Now look at MindWalk. The debate isn't whether the technology has potential. The debate is why a company with HYFT, LensAI, multiple partners, and two programs moving through neutralization is sitting at roughly an $80 million valuation. That's why I've always believed management matters. Great technology can create value. Great management can help the market recognize it.

$HYFT My criticism of Jennifer Bath’s leadership isn’t going away. I’ve been consistent about that, and I still believe management deserves scrutiny from shareholders. That said, something has changed for me since the recent data release. The story is becoming less about management and more about LensAI, HYFT, and the technology itself. MindWalk delivered the data. The platform made a prediction, the science was tested, and the results supported the prediction at the binding level. There’s still a lot of work ahead, but for the first time we’re seeing evidence that the technology may be capable of doing what it was designed to do. As an investor, that’s where my attention is shifting. Management will always matter because execution matters. But if dengue and influenza continue to validate, the conversation increasingly becomes about the capabilities of the discovery engine itself. At some point, the technology becomes the star of the show. Shareholders will still have a voice through future votes and annual meetings. My views on leadership haven’t changed. But if the technology continues to prove itself, I suspect the market, strategic partners, pharmaceutical executives, and potential acquirers will ultimately have a major influence on determining where Jennifer Bath fits in the company’s long-term future. We’re not there yet, but we’re closer today than we were a week ago.

$HYFT In my opinion, MindWalk has entered a new phase: man vs. machine. The machine is HYFT, LensAI, and the Biointelligence Platform. It's the reason many investors are here. The recent dengue data suggest the technology may finally be demonstrating its ability to translate computational predictions into real biological outcomes. The question is no longer whether the technology deserves attention. The question is whether management can keep up with it. Right now, I see a company whose greatest asset may be its technology, while its greatest challenge may be execution. If the platform continues to validate, the gap between what the technology is capable of and what management delivers could become increasingly apparent. The machine is becoming the star of the story. Now management must prove it can accelerate the opportunity—not become the bottleneck holding it back.

$HYFT One of my concerns as a shareholder is that management often appears to be reacting to the world's biggest headlines rather than getting ahead of them. Today it's dengue, influenza, Ebola, and Hantavirus. Those are important programs, but they also happen to align with the health threats currently receiving the most attention. Truly visionary leadership doesn't just follow the conversation—it helps create it. What makes this frustrating is that MindWalk may have had something special sitting inside the company for years. ImmunoPrecise eventually evolved into MindWalk as the focus shifted toward HYFT, LensAI, and the Biointelligence Platform. Looking back, it's fair to ask why the company wasn't leading with this technology much earlier. If the recent dengue data are the beginning of true platform validation, then shareholders may eventually wonder whether this technology could have been front and center years ago rather than remaining in the background. My concern isn't the science. In fact, the science may finally be validating the vision many investors saw in the platform. My concern is whether management has consistently recognized the value of what they had and whether they have the ability to stay ahead of the curve rather than reacting to it. If HYFT continues to validate, the opportunity could be enormous. The question is whether the company has the leadership necessary to fully capitalize on it.

$HYFT This isn't just about whether a single dengue study succeeds. The bigger story is whether HYFT/LensAI can consistently identify biologically meaningful targets that traditional approaches have struggled to find. Dengue has challenged researchers for decades because of its four serotypes and the complexity of generating broad protection without introducing additional risk. MindWalk's platform wasn't designed to solve only dengue—it was designed to identify functional biological patterns that may not be obvious through conventional methods. That's why today's data matter. The platform made a prediction, scientists built an immunogen around that prediction, and the resulting antibodies recognized all four dengue serotypes. More validation is needed, but this is the first public evidence that the prediction-to-biology loop may be working. If future studies demonstrate successful neutralization and a favorable ADE profile, the real breakthrough may not be a dengue vaccine. It may be proof that AI can help solve biological problems that have challenged the industry for decades. That's the opportunity I see as an investor.

$HYFT They can white label any spin offs they want to stay relevant. The fact is, its still LensAI. Where is our data update? Is it behind the same door as the SPC's? Jennifer Bath must go at the next vote!

𝗠𝗶𝗻𝗱𝗪𝗮𝗹𝗸 𝗛𝗼𝗹𝗱𝗶𝗻𝗴𝘀 𝗖𝗼𝗿𝗽. 𝗗𝗲𝗽𝗹𝗼𝘆𝘀 𝗣𝗮𝗻𝗱𝗲𝗺𝗶𝗰 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Today, MindWalk announced the launch of its Pandemic Response Platform, a deployment configuration of the Company's proprietary HYFT® biological pattern system and LensAI™ platform purpose-built for outbreak preparedness, rapid countermeasure design, and pan-strain antigen and antibody generation against RNA viruses. The problem: RNA viruses have resisted broadly protective countermeasures not because the science is young, but because the discovery approach has a structural flaw. Across RNA virus countermeasure programs, three dynamics have consistently resisted conventional solutions: •The target keeps moving. •General-purpose AI inherits the flaw rather than solving it. •The cost of being wrong resets with every outbreak. The Pandemic Response Platform operates on the virus's instruction set: the biological patterns RNA viruses must maintain across all viable variants to attach to cells, replicate, and assemble. See full release: ir.mindwalkai.com/news/news-… #Vaccines #RNA #HantaVirus #Ebola #DrugDiscovery #MindWalk @NIH @CDCGlobal @CDCgov @DARPA

Breaking: $HYFT launches a Pandemic Response Platform using its HYFT biological pattern system and LensAI platform to design pan-strain RNA virus countermeasures for governments, biodefense agencies and pharma partners.

$HYFT 팬데믹 대응 플랫폼 출시 이 플랫폼은 회사의 독자적 HYFT® 생물학적 패턴 시스템과 LensAI™ 플랫폼을 기반으로 한 배포형 구성으로, 감염병 발생 대비, 신속한 대응물질 설계, 그리고 RNA 바이러스를 대상으로 한 범균주 항원 및 항체 생성을 목적으로 구축됐다.